CoChat

Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide Receptor

Open access
Ravn, Peter, Madhurantakam, Chaithanya, Kunze, Susan, Matthews, Evelyn, Priest, Claire, O'Brien, Siobhan, Collinson, Andie, Papworth, Monika, Fritsch-Fredin, Maria, Jermutus, Lutz, Benthem, Lambertus, Gruetter, Markus, Jackson, Ronald H. · 2013 · Journal of Biological Chemistry
Cited by 86

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) is an endogenous hormonal factor (incretin) that, upon binding to its receptor (GIPr; a class B G-protein-coupled receptor), stimulates insulin secretion by beta cells in the pancreas. There has been a lack of potent inhibitors of the GIPr with prolonged in vivo exposure to support studies on GIP biology. Here we describe the generation of an antagonizing antibody to the GIPr, using phage and ribosome display libraries. Gipg013 is a specific competitive antagonist with equally high potencies to mouse, rat, dog, and human GIP receptors with a K i of 7 nm for the human GIPr. Gipg013 antagonizes the GIP receptor and inhibits GIP-induced insulin secretion in vitro and in vivo . A crystal structure of Gipg013 Fab in complex with the human GIPr extracellular domain (ECD) shows that the antibody binds through a series of hydrogen bonds from the complementarity-determining regions of Gipg013 Fab to the N-terminal α-helix of GIPr ECD as well as to residues around its highly conserved glucagon receptor subfamily recognition fold. The antibody epitope overlaps with the GIP binding site on the GIPr ECD, ensuring competitive antagonism of the receptor. This well characterized antagonizing antibody to the GIPr will be useful as a tool to further understand the biological roles of GIP. Background: GIPr mediates insulin secretion upon GIP stimulation. Results: Gipg013 is a highly specific and potent antagonist of GIPr with a fully characterized mode of action. Conclusion: Gipg013 antagonizes GIPr in vivo , as exemplified by inhibition of GIP-induced insulin secretion. Significance: This antagonizing antibody to the GIPr will be useful as a tool to further understand the biological roles of GIP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m112.426288

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 86

Metadata

Authors
Ravn, P., Madhurantakam, C., Kunze, S., Matthews, E., Priest, C., O'Brien, S., Collinson, A., Papworth, M., Fritsch-Fredin, M., Jermutus, L., Benthem, L., Gruetter, M., & Jackson, R. H.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2013-07
Volume
288
Issue
27
Pages
19760-19772
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2010993512
Cited by
86
References
9
FWCI
6.89
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide Receptor. https://app.cochat.ai/papers/10.1074/jbc.m112.426288
The paper
Ravn, P., Madhurantakam, C., Kunze, S., Matthews, E., Priest, C., O'Brien, S., Collinson, A., Papworth, M., Fritsch-Fredin, M., Jermutus, L., Benthem, L., Gruetter, M., & Jackson, R. H. (2013). Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide Receptor. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m112.426288

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.